{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T17:49:33Z","timestamp":1761155373168},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2005,9,1]],"date-time":"2005-09-01T00:00:00Z","timestamp":1125532800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Huazhong Univ. Sci. Technol. [Med. Sci.]"],"published-print":{"date-parts":[[2005,9]]},"DOI":"10.1007\/bf02896007","type":"journal-article","created":{"date-parts":[[2010,6,22]],"date-time":"2010-06-22T16:36:57Z","timestamp":1277224617000},"page":"527-529","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and safety of risedronate sodium in treatment of postmenopausal osteoporosis"],"prefix":"10.1007","volume":"25","author":[{"given":"Li","family":"Yuming","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhang","family":"Zhongzhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deng","family":"Xiuling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Lulu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"issue":"4","key":"BF02896007_CR1","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.bone.2003.12.013","volume":"34","author":"B Borah","year":"2004","unstructured":"Borah B, Dufresne T E, Chmielewski P Aet al. Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography. Bone, 2004, 34(4): 736","journal-title":"Bone"},{"issue":"2","key":"BF02896007_CR2","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00223-003-0042-4","volume":"74","author":"J T Harrington","year":"2004","unstructured":"Harrington J T, Ste-Marie L G, Brandi M Let al. Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis. Calcif Tissue Int, 2004, 74(2): 129","journal-title":"Calcif Tissue Int"},{"key":"BF02896007_CR3","first-page":"1895","volume":"85","author":"I Fogelman","year":"2000","unstructured":"Fogelman I, Ribot C, Smith Ret al. Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. J Clin Endocrinol Metab, 2000, 85: 1895","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"BF02896007_CR4","first-page":"309","volume":"104","author":"Z Rozkydal","year":"2003","unstructured":"Rozkydal Z, Janicek P. The effect of alendronate in the treatment of postmenopausal osteoporosis. Bratisl Lek Listy, 2003, 104(10): 309","journal-title":"Bratisl Lek Listy"},{"issue":"3","key":"BF02896007_CR5","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1185\/030079904125003071","volume":"20","author":"E G Lufkin","year":"2004","unstructured":"Lufkin E G, Sarkar S, Kulkarni P Met al. Antiresorptive treatment of postmenopausal osteoporosis: review of randomized clinical studies and rationale for the Evista alendronate comparison (EVA) trial. Curr Med Res Opin, 2004, 20(3): 351","journal-title":"Curr Med Res Opin"},{"key":"BF02896007_CR6","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/ar.1092030104","volume":"203","author":"D B Kimmel","year":"1982","unstructured":"Kimmel D B, Jee W S. A quantitative histologic study of bone turnover in young adult beagles. Anat Rec, 1982, 203: 31","journal-title":"Anat Rec"},{"key":"BF02896007_CR7","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2165\/00002512-199915040-00004","volume":"15","author":"D Gatti","year":"1999","unstructured":"Gatti D, Adami S. New bisphosphonates in the treatment of bone disease. Drugs Aging, 1999, 15: 285","journal-title":"Drugs Aging"},{"key":"BF02896007_CR8","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1080\/030097498441155","volume":"27","author":"N Giuliani","year":"1998","unstructured":"Giuliani N, Pedrazzoni M, Passeri Get al. Bisphosphonates inhibit IL-6 production by human osteoblastliks cells. Scand J Rheumatol, 1998, 27: 38","journal-title":"Scand J Rheumatol"},{"key":"BF02896007_CR9","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1210\/edrv.19.1.0325","volume":"19","author":"H Fleisch","year":"1998","unstructured":"Fleisch H. Bisphosphonates: mechanisms of action. Endo Revi, 1998, 19: 80","journal-title":"Endo Revi"},{"key":"BF02896007_CR10","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1359\/jbmr.1998.13.11.1668","volume":"13","author":"S P Luckman","year":"1998","unstructured":"Luckman S P, Hughs D E, Coxon F Pet al. Netrogencontaining bisphosphonates inhabit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including ras. J Bone Miner Res, 1998, 13: 1668","journal-title":"J Bone Miner Res"},{"issue":"1","key":"BF02896007_CR11","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s001980050009","volume":"11","author":"P D Ross","year":"2000","unstructured":"Ross P D, Kress B C, Parson R Eet al. Serum bone alkaline phosphatase and calcaneus bone density predict factors: A prospective study. Osteopors Int, 2000, 11 (1): 76","journal-title":"Osteopors Int"},{"issue":"3","key":"BF02896007_CR12","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/j.1572-0241.2000.01850.x","volume":"95","author":"R Dresner-pollak","year":"2000","unstructured":"Dresner-pollak R, Karmeli F, Eliakin Ret al. Increased urinary N-telopetide cross-linked type I collagen predicts bone loss in patients with inflammatory bowel disease. Am J Gastroenterol, 2000, 95(3): 699","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"BF02896007_CR13","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00198-002-1370-3","volume":"14","author":"B Hamilton","year":"2003","unstructured":"Hamilton B, McCoy K, Taggart H. Tolerability and compliance with risedronate in clinical practice. Osteoporos Int, 2003, 14(3): 259","journal-title":"Osteoporos Int"}],"container-title":["Journal of Huazhong University of Science and Technology [Medical Sciences]"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02896007.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF02896007\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF02896007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T17:27:54Z","timestamp":1558546074000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF02896007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9]]},"references-count":13,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005,9]]}},"alternative-id":["BF02896007"],"URL":"https:\/\/doi.org\/10.1007\/bf02896007","relation":{},"ISSN":["1672-0733","1993-1352"],"issn-type":[{"value":"1672-0733","type":"print"},{"value":"1993-1352","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,9]]}}}